Health ❯ Healthcare

Medications

Weight Loss Weight Loss Drugs Side Effects GLP-1 Drugs Diabetes Medications Weight Management GLP-1 Agonists Diabetes Weight Loss Medications GLP-1 Receptor Agonists

Medicare’s First Negotiated Drug Prices Take Effect Jan. 1, Cutting 2026 Costs

AARP projects roughly 50% lower out-of-pocket spending in stand-alone Part D plans with CMS estimating $1.5 billion in enrollee savings.

FDA Expands Addyi Use to Postmenopausal Women Under 65

Trump Poised to Launch Medicare CBD Pilot as Early as 2026

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65

GLP-1 Boom Hits a Crossroads as States Cut Coverage and Next‑Gen Drugs Advance

Monthly Tezepelumab Shot Lets Over Half With Severe Asthma Stop Daily Steroids, International Trial Finds

Denmark Awards Compensation to Four Patients for Eye Damage Linked to Ozempic and Wegovy

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

FDA Drops Broad Black-Box Warnings on Menopause Hormone Therapy

Unpublished AHA Study Links Long-Term Melatonin Use to Higher Heart Risks

Robbie Williams Blames Weight-Loss Injections for Worsening Vision, Plans to Continue Treatment

Robbie Williams Says His Vision Is Deteriorating, Blames Mounjaro

KFF Poll: GLP-1 Use Hits 12% of U.S. Adults as Cost Burdens Persist

Amy Schumer Wipes Instagram, Rejects ‘Pre-Weight-Loss’ Narrative

NHS GP Dr Amir Khan Issues Instagram Warning on Long-Term Omeprazole Risks

KFF Survey: States See Rising Medicaid Costs and Likely 2026 Shortfalls Despite Enrollment Declines

White House Clinches GLP-1 Price Deal as Lilly Sets Zepbound and Pill Pricing

Randomized Trial Finds Metformin Dulls Key Gains From Exercise

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays